Nordic Nanovector ASA: R&D Day to be virtual via live webcast only
OSLO, Norway, Nov. 29, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV), a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives of patients with haematological cancers, provides an update on its planned R&D Day on Tuesday, 30 November 2021 starting at 14:00 CET/ 13:00 GMT/ 08:00 ET. The meeting, which was going to take place in person in Oslo, will now be held as a virtual event via live webcast only due to increased travel restrictions driven by the Omicron coronavirus variant.
Updated Agenda
14:00 - Welcome - Jan Egberts, Chairman
14:10 - Strategic reflections - Erik Skullerud, CEO
14:30 - Relapsed follicular lymphoma: evolving treatment algorithm and unmet medical need - Leo Gordon, MD, Northwestern University
14:55 - Navigating the NHL landscape with Betalutin - Pierre Dodion, MD, Incoming CMO
15:20 - Integrating targeted radioimmunotherapy in NHL care pathways - Marco Renoldi, MD, COO
15:35 - Break
15:45 - The CMC journey to BLA and launch readiness - Lars Nieba, PhD, CTO
16:00 - Nordic Nanovector pipeline: promising value-enhancing opportunities
- Leveraging our CD37 expertise - Maureen Deehan, PhD, Head of Corporate Development and Strategy and Jostein Dahle, PhD, CSO
16:40 - Concluding Remarks - Erik Skullerud, CEO
The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.
The presentations will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Presentations/2021 from 7:00am CET the same day.
For further information, please contact:
IR enquiries
Malene Brondberg, CFO
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com
Media Enquiries
Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)
Tel: +44 207 638 9571
Email: nordicnanovector@medistrava.com
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.
Further information can be found at www.nordicnanovector.com.
Forward-looking statements
This press release contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to a duty of disclosure pursuant to Sections 4-2 and 5-12 of the Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
Share this article